0001209191-23-053791.txt : 20231027
0001209191-23-053791.hdr.sgml : 20231027
20231027174329
ACCESSION NUMBER: 0001209191-23-053791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231025
FILED AS OF DATE: 20231027
DATE AS OF CHANGE: 20231027
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Castelein Caley
CENTRAL INDEX KEY: 0001355758
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231356561
MAIL ADDRESS:
STREET 1: THOM. WEISEL HEALTHCARE VENTURES
STREET 2: ONE MONTGOMERY STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tourmaline Bio, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-481-9832
MAIL ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: Talaris Therapeutics, Inc.
DATE OF NAME CHANGE: 20201007
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-25
0
0001827506
Tourmaline Bio, Inc.
TRML
0001355758
Castelein Caley
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702
NEW YORK
NY
10010
1
0
0
0
0
Common Stock
2023-10-25
4
P
0
4200
12.07
A
500719
D
Common Stock
2023-10-27
4
P
0
15800
14.55
A
516519
D
Common Stock
458039
I
By KVP Capital, LP
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.82 to $12.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These shares are held by KVP Capital, LP ("KVP"). The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Brad Middlekauff, Attorney-in-Fact
2023-10-27